阿德福韦酯初治慢性乙型肝炎患者应答欠佳继续该药治疗的疗效分析

邱英峰; 丁永刚; 李光明

阿德福韦酯初治慢性乙型肝炎患者应答欠佳继续该药治疗的疗效分析

兰州大学第二附属医院

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3586
- HTML全文浏览量: 22
- PDF下载量: 717
- 被引次数: 0
出版历程
- 出版日期: 2011-06-20

Analysis of therapeutic effect of adefovir dipivoxil in continued treatment of chronic hepatitis B patients with poor early virological response to initial treatment

摘要

摘要: 目的探讨应用阿德福韦酯(ADV)初治慢性乙型肝炎(CHB)患者应答欠佳或失败后继续给予ADV治疗方案的安全性及疗效。方法所有CHB患者均以ADV 10 mg/d作为初始治疗,在治疗12周时,未达到HBV DNA转阴者根据HBV DNA下降值分为三组。三组均继续增加ADV治疗剂量观察。结果 120例初治患者共有94例患者入组。累计转阴率为71/120(59.17%),比较12周时转阴率为26/120(21.67%),χ2=5.837,P<0.05。各组肌酐水平治疗前后无统计学意义。结论 ADV初治病毒学应答欠佳的患者通过延长观察时间至24周及增加每日摄入剂量继续ADV治疗可以提高HBV DNA转阴率,且患者肌酐水平无明显升高。
- 肝炎,乙型,慢性 /
- 阿德福韦酯
Abstract: Objective To explore the safety and therapeutic effect of adefovir dipivoxil in continued treatment of chronic hepatitis B patients with poor early virological response to initial treatment or with failure treatment and to reduce nucleoside medication abuse.Methods All the 120 chronic hepatitis B patients took 10 mg of adefovir dipivoxil as oral dose once a day.The patients without clearance of HBV DNA after 12 weeks treatment with adefovir dipivoxil would be studied and be divided into three groups on the basis of HBV DNA level.They would take adefovir dipivoxil at increased oral dose once a day for another 12 weeks for further observation.Results 94 of 120 patients completed 24 weeks of treatment.The cumulative clearance rate of serum HBV DNA was 71/120 (59.17%) in patients with treatment for 24 weeks and 26/120 (21.67%) in patients with treatment for 12 weeks, χ2=5.837, P<0.05.There was no significant difference in serum creatinine level among the groups (P>0.05) .Conclusion By increasing oral dose of adefovir dipivoxil to 15mg or 20mg once a day and prolonging the treatment time to 24 weeks, the clearance rate of level of serum HBV DNA of patients with poor early virological response in initial treatment can be raised.The significant elevations in serum creatinine level has not been observed and clinical trial sample should be large enough to certify it.
- hepatitis B /
- chronic

HTML全文

参考文献(15)

[1]Wolters LM, Niesters Hg, de Man RA, et al.Nucleosideanalogues for chronic hepatitis B[J].Eur J Gastroenterol Hepatol, 2001, 13 (12) :1499-1506.

[2]Hadziyannis SJ, Tassopoulos NS, Heathcote EJ, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B[J].N Engl J Med, 2003, 348:800-807.

[3]Hadziyannis S, Tassopoulos N, Chang TT, et al.Three-year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed preoore mutant chronic hepatitis B patients in a long-term safety and efficacy study[J].J Hepatol, 2004, 40 (Suppl1) :17.

[4]Marcellin P, Chang TT, Lin SG, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].N Engl J Med, 2003, 348 (9) :808-816.

[5]中华医学会肝病学会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.

[6]李可军, 娄宪芝, 夏华, 等.国产阿德福韦酯治疗慢性乙型肝炎患者48周的临床研究[J].现代预防医学, 2010, 37, (17) :3386-3389.

[7]Locarnin S, Qi X, Arterburn S, et al.Incidence and predictors of emergence of adeforir resistant HBV during for years of adeforir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [J].J Hepatology, 2005, 42:A17.

[8]丁洋, 赵连荣, 窦晓光.阿德福韦酯治疗55例不同基因型慢性乙型肝炎的疗效[J].中国临床药学杂志, 2008, 17 (6) :334-336.

[9]Peters MG, Hann Hw H, Martin P, et al.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B[J].Gastroenterology, 2004, 126 (1) :91-101.

[10]Perrillo R, Hann HW, Mutimer D, et al.Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus[J].Gastroenterology, 2004, 126 (1) :81-90.

[11]Lampertico P, Marzano A, Levrero M, et al.Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B[J].J Hepatol, 2007, 46 (Suppl 1) :s191.

[12]Lee HI, Lee JH, Tak WY, et al.Overlapping of lamivudine and adefovir before switching to adefovir monotherapy in lamivudine resistant chronic hepatitis B:is it necessary[J].J Hepatol, 2007, 46 (Suppl 1) :s191.

[13]Poorten D, Prakoso E, Khoo TL, et al.Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B[J].J Gastroenterol Hepatol, 2007, 22 (9) :1500-1506.

[14]Liaw YF, Lee CM, Chien RN, et al.Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis[J].J Viral Hepatol, 2006, 13 (4) :250-255.

[15]Hézode C, Chevaliez S, Bouvier-Alias M, et al.Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily[J].J Hepatol, 2007, 46 (5) :791-796.

施引文献

资源附件(0)

访问统计